Michael K. Wong

6.8k total citations
100 papers, 2.2k citations indexed

About

Michael K. Wong is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael K. Wong has authored 100 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Oncology, 24 papers in Molecular Biology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael K. Wong's work include Cancer Immunotherapy and Biomarkers (30 papers), CAR-T cell therapy research (22 papers) and Immunotherapy and Immune Responses (13 papers). Michael K. Wong is often cited by papers focused on Cancer Immunotherapy and Biomarkers (30 papers), CAR-T cell therapy research (22 papers) and Immunotherapy and Immune Responses (13 papers). Michael K. Wong collaborates with scholars based in United States, Canada and Australia. Michael K. Wong's co-authors include A I Gotlieb, B. Lowell Langille, Adi Diab, James A. DeCaprio, Isaac Brownell, Paul W. Harms, Kelly L. Harms, Patrick S. Moore, Paul Nghiem and Rodabe N. Amaria and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Michael K. Wong

94 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael K. Wong United States	26	1.1k	701	415	336	246	100	2.2k
Young A Kim South Korea	31	1.3k 1.1×	788 1.1×	542 1.3×	484 1.4×	417 1.7×	111	2.7k
Andrew Haydon Australia	28	1.9k 1.7×	751 1.1×	464 1.1×	398 1.2×	269 1.1×	143	3.1k
Xiaoming Zhou China	21	596 0.5×	652 0.9×	317 0.8×	386 1.1×	293 1.2×	100	1.9k
Francesco Spagnolo Italy	27	1.7k 1.5×	951 1.4×	421 1.0×	603 1.8×	235 1.0×	111	2.5k
Richard J. Edmondson United Kingdom	36	1.4k 1.3×	1.3k 1.9×	269 0.6×	259 0.8×	507 2.1×	128	3.6k
Jing Chen China	29	971 0.9×	969 1.4×	244 0.6×	651 1.9×	298 1.2×	172	3.1k
Alexandre Reuben United States	26	1.6k 1.5×	1.2k 1.7×	394 0.9×	921 2.7×	258 1.0×	85	2.8k
Zhiyong Yu China	24	528 0.5×	734 1.0×	307 0.7×	165 0.5×	374 1.5×	103	1.8k
Loren Joseph United States	36	835 0.8×	1.4k 2.0×	402 1.0×	406 1.2×	657 2.7×	75	3.2k
Elisabetta Rossi Italy	28	709 0.6×	788 1.1×	355 0.9×	201 0.6×	662 2.7×	104	2.3k

Countries citing papers authored by Michael K. Wong

Since Specialization

Citations

This map shows the geographic impact of Michael K. Wong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael K. Wong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael K. Wong more than expected).

Fields of papers citing papers by Michael K. Wong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael K. Wong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael K. Wong. The network helps show where Michael K. Wong may publish in the future.

Co-authorship network of co-authors of Michael K. Wong

This figure shows the co-authorship network connecting the top 25 collaborators of Michael K. Wong. A scholar is included among the top collaborators of Michael K. Wong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael K. Wong. Michael K. Wong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kreidieh, Firas & Michael K. Wong. (2025). New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms. Current Pharmaceutical Design. 32(4). 285–300.

Amaria, Rodabe N., Jennifer L. McQuade, Michael A. Davies, et al.. (2024). OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.. Journal of Clinical Oncology. 42(16_suppl). 9515–9515. 17 indexed citations

Saberian, Chantal, Denái R. Milton, Julie M. Simon, et al.. (2024). Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma. Neuro-Oncology Practice. 11(4). 452–463. 1 indexed citations

Na’ara, Shorook, Frederico O. Gleber‐Netto, Tongxin Xie, et al.. (2023). Beta-Blocker Use Is Associated With Worse Relapse-Free Survival in Patients With Head and Neck Cancer. JCO Precision Oncology. 7(7). e2200490–e2200490. 9 indexed citations

Wong, Michael K., et al.. (2023). Neoadjuvant Approaches to Non-Melanoma Skin Cancer. Cancers. 15(23). 5494–5494. 5 indexed citations

Burton, Elizabeth M., Lauren Simpson, Víctor G. Prieto, et al.. (2023). Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.. Journal of Clinical Oncology. 41(16_suppl). 9583–9583. 1 indexed citations

Spreafico, Anna, Alya Heirali, Daniel Vilarim Araújo, et al.. (2023). First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Annals of Oncology. 34(6). 520–530. 48 indexed citations

Bishop, Andrew J., Yi‐Ju Chiang, B. Ashleigh Guadagnolo, et al.. (2023). Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiotherapy and Oncology. 188. 109892–109892. 2 indexed citations

Patel, Anisha B., Rodabe N. Amaria, Susan Y. Chon, et al.. (2021). Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit. Cancer. 128(5). 975–983. 13 indexed citations

10.

Tam, Samantha, Xiaoning Luo, Bonnie S. Glisson, et al.. (2021). Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head & Neck. 43(5). 1592–1603. 3 indexed citations

11.

Lucci, Anthony, Carolyn Hall, Sapna P. Patel, et al.. (2020). Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clinical Cancer Research. 26(8). 1886–1895. 52 indexed citations

12.

Aung, Phyu P., Edwin R. Parra, Souptik Barua, et al.. (2019). B7-H3 Expression in Merkel Cell Carcinoma–Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clinical Cancer Research. 25(11). 3455–3467. 29 indexed citations

13.

Harms, Paul W., Kelly L. Harms, Patrick S. Moore, et al.. (2018). The biology and treatment of Merkel cell carcinoma: current understanding and research priorities. Nature Reviews Clinical Oncology. 15(12). 763–776. 203 indexed citations

14.

Glitza, Isabella C., Michelle Rohlfs, Nandita Guha‐Thakurta, et al.. (2018). Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 3(1). e000283–e000283. 47 indexed citations

15.

Diab, Adi, Michael E. Hurwitz, Nizar M. Tannir, et al.. (2017). PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies. Annals of Oncology. 28. v426–v427. 4 indexed citations

16.

Curti, Brendan D., Gregory A. Daniels, David F. McDermott, et al.. (2017). Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. Journal for ImmunoTherapy of Cancer. 5(1). 102–102. 27 indexed citations

17.

Silva, Diane M. Da, Adam B. Raff, Heike E. Brand, et al.. (2014). Suppression of Langerhans cell activation is conserved amongst human papillomavirus α and β genotypes, but not a µ genotype. Virology. 452-453. 279–286. 25 indexed citations

18.

Wong, Michael K., Hongbo Yang, James Signorovitch, et al.. (2013). Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Current Medical Research and Opinion. 30(4). 537–545. 29 indexed citations

19.

Ramanathan, Ramesh K., Jimmy J. Hwang, William C. Zamboni, et al.. (2004). Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial. Cancer Investigation. 22(6). 858–865. 118 indexed citations

20.

Wong, Michael K., et al.. (1992). Effect of initial oxidation on ascorbic acid browning in stored kiwifruit juice and model concentrates.. LWT. 25(6). 574–578. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact